Background. Posaconazole is approved in adults for prophylaxis and treatment of invasive fungal disease. Two formulations that offer weight-based dosing-intravenous (IV) and oral powder for suspension (PFS)-are being evaluated in children. A population pharmacokinetic (popPK) approach was used to characterize and predict the PK exposure of posaconazole PFS and IV formulations in children to identify dosages associated with achieving a target PK of 1200 ng/mL as the mean C avg and individual C avg ≥500 ng/mL and <2500 ng/mL in ~90% of patients.
